European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

by Marie Weil
December 21, 2021
A A
Share on LinkedinShare on Twitter
  • Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Cladribine selectively targets B and T cells, which are key contributors to autoimmune diseases such as NMOSD and gMG
  • Focused expansion in neuroinflammatory diseases builds on existing neurology portfolio in Multiple Sclerosis (MS) 

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.

“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.

Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.

Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.

Tags: < Invest

Related Industries

Health

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio

January 25, 2023
Health


Philips and Masimo expand partnership to improve telehealth for patients and clinicians around the world

January 19, 2023
Health

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 10, 2023
Health

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

January 10, 2023
Health

Boehringer Ingelheim announces appointments to Board of Managing Directors

December 21, 2022
Health

Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology

December 20, 2022

Continental Showcases Curved Display with Invisible Control Panel and Innovation for Driver Identification

January 6, 2023

...

NXP Introduces Advanced Automotive Radar One-Chip Family for Next-Gen ADAS and Autonomous Driving Systems

January 6, 2023

...

Johnson Controls Acquires Hybrid Energy to Enhance Industrial Heat Pump Portfolio

January 14, 2023

...

IHG Hotels & Resorts opens global headquarters in Windsor

January 12, 2023

...

A.P. Moller – Maersk announces new executive leadership team

January 11, 2023

...

Interview with Jaime Argüelles, CEO of Duro Felguera

January 25, 2023

...

TotalEnergies EP Canada acquires an additional interest in Fort Hills, ahead of its planned spin-off

January 28, 2023

...

Das neue ZF-Vorstandsteam (von links nach rechts): Michael Frick, Dr. Martin Fischer, Vorstandsvorsitzender Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula und Stephan von Schuckmann.
//
ZF’s newly formed Board of Management team (from left to right): Michael Frick, Dr. Martin Fischer, CEO Dr. Holger Klein, Dr. Peter Laier, Sabine Jaskula and Stephan von Schuckmann.

ZF Kicks Off 2023 With New Executive Management Team

January 13, 2023

...

Siemens and Skyway collaborate to develop infrastructure to pave way for Vertiports

January 27, 2023

...

ZF Acquires Intellic to Advance Next Generation Fleet Connectivity for Commercial Vehicles

January 12, 2023

...

Asia Pacific Business Asia Pacific Business Asia Pacific Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist